Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

Journal of Gastroenterology

Volumn 48, Issue 11, 2013, Pages 1234-1241

  Oyama, Katsunobu ^a   Fushida, Sachio ^a   Kaji, Masahide ^b   Takeda, Toshiya ^c   Kinami, Shinichi ^d   Hirono, Yasuo ^e   Yoshimoto, Katsuhiro ^f   Yabushita, Kazuhisa ^g   Hirosawa, Hisashi ^h   Takai, Yuki ⁱ   Nakano, Tatsuo ^j   Kimura, Hironobu ^k   Yasui, Toshiaki ^l   Tsuneda, Atsushi ^m   Tsukada, Tomoya ^a   Kinoshita, Jun ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Public Central Hospital of Matto Ishikawa   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF FUKUI   (Japan)

^f Toyama Rosai Hospital   (Japan)

^g Kohseiren Takaoka Hospital   (Japan)

^h TOYAMA CITY HOSPITAL   (Japan)

ⁱ Keiju Medical Center   (Japan)

^j Asanogawa General Hospital   (Japan)

^k 2 16 76 Owari cho   (Japan)

^l Kanazawa Social Insurance Hospital   (Japan)

^m Kurobe City Hospital   (Japan)

more..

Author keywords

Anorexia; Aprepitant; CINV; Gastric cancer; QOL

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANISETRON;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIETARY INTAKE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL LIVING INDEX EMESIS QUESTIONNAIRE; HICCUP; HUMAN; MALE; MIDDLE AGED; MORNING DOSAGE; MORNING SICKNESS; MOTION SICKNESS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STOMACH CANCER; VERY ELDERLY; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEXAMETHASONE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASM STAGING; OXONIC ACID; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; VOMITING;

EID: 84889881843     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0746-1     Document Type: Article

References (32)

1. Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2002;6:94-102.
2. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055-61.
3. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880-6.
4. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331-40.
5. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-8.
6. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004;15:526-36.
7. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639-48.
8. Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis. J Natl Compr Canc Netw. 2007;5:12-33.
9. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7.
10. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191-6.
11. Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996;78:2193-8.
12. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol. 1981;7:11-4.
13. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-94.
14. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33:66-74.
15. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:1174-8.
16. Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37:2398-404.
17. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39:1074-80.
18. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-9.
19. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-8.
20. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-6.
21. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Supplement 5):v232-43.
22. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29: 4189-98.
23. JSCO Guidelines for Antiemetics in Oncology 2010. 1st ed. Tokyo: Kanehara shuppan; 2010.
24. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
25. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11:522-7.
26. Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, et al. Development of a Japanese version of the FLIE. Gan To Kagaku Ryoho. 2002;29:281-91.
27. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14:348-53.
28. Tonini G, Vincenzi B, Santini D. New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol. 2005;1:143-9.
29. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-7.
30. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone and aprepitant. J Support Oncol. 2006;4:403-8.
31. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008;112:2080-7.
32. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17:589-94.